Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 9/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 6/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15701030 | 0.80 | GRM1 (0.47) | CYP2C9CYP2C8GRM1CYP2D6CYP3A4 | |
| SCHEMBL19443341 | 0.77 | GRM1 (0.45) | CYP2C9CYP2C8GRM1CYP2D6CYP3A4 | |
| SCHEMBL19443383 | 0.77 | GRM1 (0.45) | CYP2C9CYP2C8GRM1CYP2D6CYP3A4 | |
| SCHEMBL15701019 | 0.77 | CYP2C9 (0.47) | CYP2C9CYP2C8GRM1CYP2D6CYP3A4 | |
| SCHEMBL15707569 | 0.77 | CYP2C9 (0.56) | CYP2C9CYP2C8GRM1CYP2D6CYP3A4 | |
| SCHEMBL15707360 | 0.76 | CYP2C9 (0.56) | CYP2C9CYP2C8GRM1CYP2D6CYP3A4 | |
| SCHEMBL15707399 | 0.75 | CYP2C9 (0.49) | CYP2C9CYP2C8GRM1CYP2D6CYP3A4 | |
| Benzene SCHEMBL27888677 | 0.73 | GRM4 (0.52) | GRM1GRM4MAP3K5 | |
| SCHEMBL15707235 | 0.73 | JAK2 (0.53) | CYP2C9CYP2C8GRM1GRM4ROCK2 | |
| SCHEMBL15070508 | 0.73 | RAB9A (0.59) | CYP2C9CYP2C8GRM1CYP3A4GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334249-B2 | Inhibitors of cytomegalovirus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-10 | — | — | US | disclosed |
| US-20150284348-A1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284348-A1 | INHIBITORS OF CYTOMEGALOVIRUS | CDKN1A, CCNA1, IFNAR1 | CYP2C9 2373/4885CYP2C8 2028/4885GRM1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.